Security
CorMedix Inc. Common Stock · CRMD
CRMDNASDAQCommon stockCurrentCIK 1410098Updated Nov 3, 2026
CRMD price & chart
Loading TradingView…
NASDAQ:CRMD on TradingView ↗About the company
CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases in the United States. CorMedix is focused on selling and marketing products in institutional settings of care in the US and has field based medical and commercial infrastructure deployed in hospitals, clinics and infusion centers. For more information visit: www.cormedix.com.
In the news
Today's Stocks in the News ↗
Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update News provided by Talphera, Inc. Nov 12, 2025, 16:05 ET Share this article Share to X Share this article Share to X Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash a ↗
Seeking Alpha
Healthcare stocks with strong revenue growth and attractive valuations ↗
Cormedix gets FDA priority review for Rezzayo label expansion ↗
Actinium Pharmaceuticals names former CorMedix executive as CFO ↗
SEC disclosures
CorMedix Inc. files 8-K: Material Event ↗
Recent filings
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01, 9.01
Show 5 more recent filings
Other Events
Items 8.01
Changes in Registrant's Certifying Accountant
Items 4.01
S-8 POS filing
Submission of Matters to a Vote of Security Holders
Items 5.07
Regulation FD Disclosure
Items 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 750,861,478Source | 77,586,194Source | 904,052,000Source | 252,599,103Source | 57,730,594Source | 815,637,000Source | 149,582,766Source | 68,023,742Source | 826,142,000Source | 118,845,673Source | 82,059,957Source | 62,038,259Source |
| Property, Plant and Equipment, NetUSD | 4,347,360Source | 1,899,875Source | 7,852,000Source | 1,641,152Source | 1,915,569Source | 6,166,000Source | 1,728,199Source | 1,905,704Source | 5,959,000Source | 1,828,016Source | 1,866,224Source | 1,609,679Source |
| GoodwillUSD | 17,515,265Source | — | 30,002,000Source | — | — | 30,002,000Source | — | — | 30,002,000Source | — | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 390,011,711Source | 1,896,104Source | 358,472,000Source | 1,740,260Source | — | 368,772,000Source | 1,792,208Source | — | 379,072,000Source | 1,844,156Source | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 48,493,076Source | 35,286,138Source | 256,692,000Source | 159,309,000Source | 28,540,633Source | 178,087,000Source | 66,286,000Source | 35,180,529Source | 144,837,000Source | 40,650,770Source | 43,642,684Source | 43,148,323Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 158,574,116Source | 17,387,446Source | 161,305,000Source | 42,911,634Source | 206,337Source | 154,807,000Source | 54,611,147Source | — | 171,233,000Source | 51,653,583Source | — | — |
| Inventory, NetUSD | 28,916,616Source | 6,649,495Source | 38,583,000Source | 9,634,438Source | 4,011,560Source | 30,731,000Source | 7,487,708Source | 2,320,396Source | 29,716,000Source | 7,599,535Source | 2,106,345Source | — |
| Assets, CurrentUSD | 259,535,273Source | 73,154,269Source | 480,554,000Source | 248,056,889Source | 53,194,379Source | 383,113,000Source | 144,861,576Source | 63,409,566Source | 367,051,000Source | 114,575,436Source | 79,450,400Source | 59,551,175Source |
| Prepaid Expense and Other Assets, CurrentUSD | 16,327,730Source | 2,916,889Source | 23,974,000Source | 4,675,885Source | 3,139,022Source | 19,488,000Source | 5,124,924Source | 2,166,267Source | 17,571,000Source | 3,481,868Source | 882,214Source | 623,672Source |
| Operating Lease, Right-of-Use AssetUSD | 3,173,567Source | 530,862Source | — | 413,652Source | 568,168Source | — | 453,633Source | 604,634Source | 3,020,000Source | 492,697Source | 640,278Source | 775,085Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 376,732,072Source | 18,873,926Source | 443,219,000Source | 31,968,916Source | 11,546,663Source | 378,588,000Source | 34,694,718Source | 10,011,022Source | 420,835,000Source | 34,188,723Source | 11,917,528Source | 6,978,523Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 92Source | 182Source | 0Source | 92Source | 182Source | 0Source | 92Source | 182Source | — | 137Source | 182Source | 182Source |
| Common Stock, Value, IssuedUSD | 78,350Source | 57,886Source | 78,000Source | 74,621Source | 55,274Source | 78,000Source | 67,711Source | 54,959Source | 79,000Source | 64,411Source | 54,938Source | 42,815Source |
| Additional Paid in CapitalUSD | 564,558,498Source | 411,659,517Source | 572,739,000Source | 519,634,193Source | 396,360,369Source | 574,943,000Source | 433,721,824Source | 394,040,254Source | 581,800,000Source | 424,131,789Source | 391,693,214Source | 330,294,782Source |
| Retained Earnings (Accumulated Deficit)USD | -190,595,174Source | -353,094,437Source | -111,986,000Source | -299,158,154Source | -350,317,625Source | -137,974,000Source | -318,986,135Source | -336,166,136Source | -176,575,000Source | -339,630,033Source | -321,700,013Source | -275,360,786Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 87,640Source | 89,120Source | 2,000Source | 79,435Source | 85,731Source | 2,000Source | 84,556Source | 83,461Source | 3,000Source | 90,646Source | 94,108Source | 82,743Source |
| Stockholders' Equity Attributable to ParentUSD | 374,129,406Source | 58,712,268Source | 460,833,000Source | 220,631,000Source | 46,183,931Source | 437,049,000Source | 114,888,000Source | 58,012,720Source | 405,307,000Source | 84,656,950Source | 70,142,429Source | 55,059,736Source |
| Liabilities and EquityUSD | 750,861,478Source | 77,586,194Source | 904,052,000Source | 252,599,103Source | 57,730,594Source | 815,637,000Source | 149,582,766Source | 68,023,742Source | 826,142,000Source | 118,845,673Source | 82,059,957Source | 62,038,259Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 133,643,797Source | 18,480,959Source | 187,396,000Source | 31,710,843Source | 11,111,417Source | 128,776,000Source | 34,390,626Source | 9,534,434Source | 174,269,000Source | 33,839,632Source | 11,400,515Source | 6,310,891Source |
| Operating Lease, Liability, CurrentUSD | 844,431Source | 163,449Source | — | 177,172Source | 159,077Source | — | 172,495Source | 154,801Source | 853,000Source | 167,922Source | 150,619Source | 134,801Source |
| Accounts Payable, CurrentUSD | 20,454,367Source | 1,343,833Source | 10,238,000Source | 5,815,366Source | 3,344,803Source | 12,827,000Source | 1,933,136Source | 2,826,322Source | 7,884,000Source | 1,720,177Source | 4,279,679Source | 2,202,149Source |
| Operating Lease, Liability, NoncurrentUSD | 2,411,243Source | 392,967Source | — | 258,073Source | 435,246Source | — | 304,092Source | 476,588Source | 2,253,000Source | 349,091Source | 517,013Source | 667,632Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 109,091,898Source | 16,973,677Source | 173,244,000Source | 25,718,305Source | 7,607,537Source | 112,773,000Source | 32,284,995Source | 6,553,311Source | 161,921,000Source | 31,951,533Source | 6,970,217Source | 3,973,941Source |
| Short-term InvestmentsUSD | 7,223,735Source | 10,743,562Source | 0Source | 31,402,850Source | 17,069,660Source | 0Source | 11,216,989Source | 23,370,989Source | 3,694,000Source | 11,036,857Source | 32,388,130Source | 15,644,062Source |
| Deferred Income Tax Liabilities, Net | — | — | —Source | — | — | — | — | — | — | — | — | — |
| Other Liabilities, Noncurrent | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Accounts Receivable, after Allowance for Credit Loss | — | — | —Source | — | — | —Source | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 4,065,541Source | 1,227,476Source | 4,084,000Source | 2,677,000Source | 4,582,000Source | 3,500,000Source | 13,832,000Source | 6,129,408Source | 5,493,751Source | 4,069,520Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -16,445,000Source | 2,965,000Source | 90,924,000Source | 51,790,583Source | — | — |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 1,015,000Source | -112,000Source | 3,478,000Source | 5,493,190Source | 2,106,345Source | -3,008Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 4,943,000Source | 213,000Source | 3,329,000Source | -2,559,491Source | 2,077,479Source | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | -59,700,000Source | — | — | — | 12,964,000Source | 0Source | -25,797,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 42,382,000Source | 19,737,000Source | 175,046,000Source | -50,614,653Source | -38,409,480Source | -24,356,732Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | 308,511,000Source | — | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 2,965,000Source | -195,000Source | -308,430,000Source | 21,230,713Source | -17,061,685Source | -3,709,364Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 729,000Source | 10,000Source | 2,260,000Source | 115,730Source | 327,300Source | 219,360Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 1,527,000Source | 1,019,000Source | 1,988,000Source | 289,622Source | 198,443Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -12,097,000Source | 6,093,000Source | 238,453,000Source | 26,318,595Source | 55,916,804Source | 17,898,241Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 33,250,000Source | 25,635,000Source | 105,069,000Source | -3,067,054Source | 448,447Source | -10,176,532Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 49,481,309Source | 35,391,222Source | 257,680,000Source | 159,414,000Source | 179,075,000Source | 66,391,000Source | 145,825,000Source | 40,756,138Source | 43,823,192Source | 43,374,745Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 2,817,000Source | 10,000Source | 17,000Source | 36,405Source | 34,296Source | 26,516Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 62,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 0Source | 0Source | — | -1,709Source | 2,808Source | -8,677Source |
| Additional Financial Items | ||||||||||||
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | — | 398,000Source | — | — | — |
| Amortization of Intangible AssetsUSD | — | — | 3,600,000Source | — | — | — | — | 51,948Source | 13,872,000Source | 155,844Source | — | — |
| DepreciationUSD | — | — | — | — | — | — | — | 109,994Source | 677,000Source | 153,937Source | 70,755Source | 84,618Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -72,727Source | -33,325Source | — | -16,295Source | — | -38,172Source | -52,000Source | -30,788Source | -28,994Source | 37,145Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | — | — | 86,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 25,451,017Source | 6,580,834Source | 15,085,000Source | 9,504,000Source | 21,720,000Source | 9,693,000Source | 68,220,000Source | 29,959,150Source | — | — |
| GoodwillUSD | — | — | 17,515,265Source | — | 30,002,000Source | — | 30,002,000Source | — | 30,002,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | 2,029,000Source | — | — | 1,700,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -46,339,227Source | — |
| Income Tax Expense (Benefit)USD | — | — | -55,986,802Source | — | 12,745,000Source | 522,000Source | 17,044,000Source | 0Source | -13,039,000Source | -1,394,770Source | — | -585,617Source |
| InterestExpenseNonoperatingUSD | — | — | 948,242Source | 10,007Source | — | 6,671Source | — | 10,007Source | 2,782,000Source | 36,405Source | — | — |
| Investment Income, InterestUSD | — | — | 1,560,272Source | 553,856Source | — | 828,949Source | — | 566,797Source | 3,846,000Source | 2,578,792Source | — | — |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | 3,090,909Source | — | 2,546,000Source | 0Source | -3,546,000Source | 0Source | 5,364,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | 108,562,980Source | -2,776,812Source | 25,988,000Source | 19,828,000Source | 38,601,000Source | 20,644,000Source | 163,055,000Source | -17,930,020Source | -46,339,227Source | -29,701,705Source |
| Nonoperating Income (Expense)USD | — | — | 1,230,212Source | 510,524Source | -4,177,000Source | 806,000Source | -8,013,000Source | 519,000Source | -125,000Source | 3,031,599Source | — | — |
| Operating ExpensesUSD | — | — | 41,734,707Source | 14,056,853Source | 34,216,000Source | 18,330,000Source | 41,464,000Source | 17,360,000Source | 125,607,000Source | 62,638,025Source | 48,957,788Source | 30,685,642Source |
| Operating Lease, ExpenseUSD | — | — | — | 51,000Source | — | 52,000Source | — | 50,000Source | — | 204,000Source | 207,000Source | 208,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | 2,618,561Source | 336,646Source |
| Payments of Financing CostsUSD | — | — | 49,192Source | — | — | — | 135,000Source | 0Source | 188,000Source | — | — | — |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | — | 5,000,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 0Source | 6,762,000Source | 7,788,000Source | 18,881,587Source | 12,949,110Source | 17,769,616Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 1,179,000Source | 350,000Source | 6,389,000Source | 7,724,129Source | 287,738Source | — |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | -4,511Source | — | -4,830Source | 9,683Source | 5,055Source |
| Depreciation, Depletion and Amortization | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Payments for Repurchase of Common Stock | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Other Operating Income (Expense), Net | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Revenue from Contract with Customer, Including Assessed Tax | — | — | —Source | —Source | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | 311,709,000Source | 43,472,170Source | — | 65,408Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | — | —Source | —Source | —Source | —Source | —Source | — | —Source |
| Selling, General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 35,802,663Source | 20,006,093Source |
| Operating Income (Loss)USD | — | — | 51,345,966Source | -3,287,336Source | 42,910,000Source | 19,544,000Source | 63,658,000Source | 20,125,000Source | 150,141,000Source | -22,356,389Source | -48,957,788Source | -30,623,968Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | 2,618,561Source | 336,646Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 52,576,178Source | -2,776,812Source | 38,733,000Source | 20,350,000Source | 55,645,000Source | 20,644,000Source | 150,016,000Source | -19,324,790Source | — | -30,287,322Source |
| Income Tax Expense (Benefit)USD | — | — | -55,986,802Source | — | 12,745,000Source | 522,000Source | 17,044,000Source | 0Source | -13,039,000Source | -1,394,770Source | — | -585,617Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 108,562,980Source | -2,776,812Source | 25,988,000Source | 19,828,000Source | 38,601,000Source | 20,644,000Source | 163,055,000Source | -17,930,020Source | -46,339,227Source | -29,701,705Source |
| Earnings Per Share, BasicUSD per share | — | — | 1.42Source | -0.05Source | 0.33Source | 0.29Source | 0.48Source | 0.32Source | 2.25Source | -0.3Source | -0.91Source | -0.74Source |
| Earnings Per Share, DilutedUSD per share | — | — | 1.26Source | -0.05Source | 0.29Source | 0.28Source | 0.43Source | 0.3Source | 2.04Source | -0.3Source | -0.91Source | -0.74Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 75,930,243Source | 58,825,221Source | 78,444,000Source | 67,928,000Source | 79,509,000Source | 65,244,000Source | 72,034Source | 58,871,582Source | 50,902,931Source | 40,274,273Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 86,214,170Source | 58,825,221Source | 92,479,000Source | 71,919,000Source | 92,985,000Source | 68,975,000Source | 80,308Source | 58,871,582Source | 50,902,931Source | 40,274,273Source |
| Interest Expense (non-operating)USD | — | — | 948,242Source | 10,007Source | — | 6,671Source | — | 10,007Source | 2,782,000Source | 36,405Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 3,600,000Source | — | — | — | — | 51,948Source | 13,872,000Source | 155,844Source | — | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 12,758,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -72,727Source | -33,325Source | — | -16,295Source | — | -38,172Source | -52,000Source | -30,788Source | -28,994Source | 37,145Source |
| General and Administrative ExpenseUSD | — | — | 25,451,017Source | 6,580,834Source | 15,085,000Source | 9,504,000Source | 21,720,000Source | 9,693,000Source | 68,220,000Source | 29,959,150Source | — | — |
| Gross ProfitUSD | — | — | 93,080,673Source | 10,769,517Source | 77,126,000Source | 37,874,000Source | 105,122,000Source | 37,485,000Source | 275,748,000Source | 40,281,636Source | — | 61,674Source |
| Income (Loss) Attributable to Parent, before TaxUSD | — | — | 52,576,178Source | -2,776,812Source | 38,733,000Source | 20,350,000Source | 55,645,000Source | 20,644,000Source | 150,016,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | 2,029,000Source | — | — | 1,700,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 150,016,000Source | -19,065,449Source | -45,946,020Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -46,339,227Source | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 34,296Source | 26,515Source |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | 1,395,000Source | — | — |
| Interest Income, OtherUSD | — | — | — | — | — | — | — | — | — | — | 2,681,851Source | 326,016Source |
| Investment Income, InterestUSD | — | — | 1,560,272Source | 553,856Source | — | 828,949Source | — | 566,797Source | 3,846,000Source | 2,578,792Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 1,230,212Source | 510,524Source | -4,177,000Source | 806,000Source | -8,013,000Source | 519,000Source | -125,000Source | 3,031,599Source | — | — |
| Operating ExpensesUSD | — | — | 41,734,707Source | 14,056,853Source | 34,216,000Source | 18,330,000Source | 41,464,000Source | 17,360,000Source | 125,607,000Source | 62,638,025Source | 48,957,788Source | 30,685,642Source |
| Operating Lease, ExpenseUSD | — | — | — | 51,000Source | — | 52,000Source | — | 50,000Source | — | 204,000Source | 207,000Source | 208,000Source |
| Research and Development ExpenseUSD | — | — | 5,097,644Source | 727,119Source | 6,684,000Source | 2,442,000Source | 7,212,000Source | 3,193,000Source | 19,333,000Source | 3,942,270Source | 13,155,125Source | 10,679,549Source |
| Selling and Marketing ExpenseUSD | — | — | 11,186,046Source | 6,748,900Source | 12,447,000Source | 6,384,000Source | 12,532,000Source | 4,474,000Source | 38,054,000Source | 28,736,605Source | — | — |
| Total Revenue | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
| Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Other Operating Income (Expense), Net | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Revenue from Contract with Customer, Including Assessed Tax | — | — | —Source | —Source | — | — | — | — | — | — | — | — |
| Undistributed Earnings (Loss) Allocated to Participating Securities, Basic | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
Filing attachments
ea031044501ex99-1.htm · 8-K · 2026-11-02
Exhibit 99.1 CORMEDIX THERAPEUTICS PROVIDES BUSINESS UPDATE, REAFFIRMS 2026 TOTAL REVENUE GUIDANCE, AND REPORTS THIRD Quarter Cash Position Parsippany, NJ - November 2, 2026 - CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call expected to be held on November 12, 2026 to discuss the Company’s complete quarterly financial performance. Business Updates CorMedix announces unaudited cash and cash equivalents on hand as of September 30, 2026 o…
Read attachment ↗ea030895701ex99-1.htm · 8-K · 2026-10-19
Exhibit 99.1 CORMEDIX ANNOUNCES FDA ACCEPTANCE FOR PRIORITY REVIEW OF SUPPLEMENTAL NDA FOR REZZAYO® (REZAFUNGIN) FOR PROPHYLAXIS OF INVASIVE FUNGAL DISEASES Parsippany, NJ - October 19, 2026 - CorMedix Therapeutics (Nasdaq: CRMD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) seeking approval of REZZAYO® (rezafungin for injection) for the prophylaxis of invasive fungal disease. The sNDA was submitted by Mund…
Read attachment ↗crmd-8xkxaugust72026xex991.htm · 8-K · 2026-08-07
EX-99.1 2 crmd-8xkxaugust72026xex991.htm EX-99.1 Document Exhibit 99.1 UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY IN RE CORMEDIX INC. C.A. No. 2:21-cv-18493-JXN-LDW (Consolidated with Civil Action No.: 23-cv-00150 and Civil Action No.: 23-cv-00406) DERIVATIVE LITIGATION TO: ALL PERSONS OR ENTITIES WHO HOLD OR BENEFICIALLY OWN, DIRECTLY OR INDIRECTLY, CORMEDIX INC. (“CORMEDIX” OR THE “COMPANY”) COMMON STOCK AS OF JANUARY 19, 2026 (“CURRENT…
Read attachment ↗crmd-8xkxaugust72026xex992.htm · 8-K · 2026-08-07
EX-99.2 3 crmd-8xkxaugust72026xex992.htm EX-99.2 Document Exhibit 99.2 UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY IN RE CORMEDIX INC. DERIVATIVE LITIGATION C.A. No. 2:21-cv-18493-JXN-LDW (Consolidated with Civil Action No.: 23-cv-00150 and Civil Action No.: 23-cv-00406) STIPULATION AND AGREEMENT OF SETTLEMENT This Stipulation and Agreement of Settlement (the “Stipulation”) dated January 19, 2026, is entered into by and amo…
Read attachment ↗ea029389501ex99-1.htm · 8-K · 2026-06-08
EX-99.1 2 ea029389501ex99-1.htm PRESS RELEASE DATED JUNE 8, 2026 Exhibit 99.1 U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT AFFIRMS VICTORY FOR CORMEDIX THERAPEUTICS IN MINOCIN® PATENT LITIGATION Parsippany, NJ - June 8, 2026 - CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the Northern District of Illinois that the patents covering its product MINOCIN ® for Inject…
Read attachment ↗ea028764001ex99-1.htm · 8-K · 2026-04-27
EX-99.1 2 ea028764001ex99-1.htm PRESS RELEASE DATED APRIL 27, 2026 Exhibit 99.1 CORMEDIX Therapeutics AnnounceS POSITIVE Topline Results from PHASE III respect TriaL assessing Rezzayo® for the PROPHYLAXIS of invasive fungal diseases in ALLOGENEIC Haematopoietic Stem Cell Transplantation PATIENTS - The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 - - Study showed favorable benefit for toxicity related discontin…
Read attachment ↗